1.Creation of a growth engine for the bio-medicine industry with the establishment of a Promotion Center
- On October 11th, a public forum was held at Daejeon Convention Center to discuss the establishment of a promotion center and a new R&D project to support the genetic medicine industry.
- More than 70 experts in the bio-medicine sector took part in discussions regarding a plan to build a promotion center and infrastructure. 
 

A Public Forum for the Establishment of a Promotion Center and a New R&D Project to Support the Genetic Medicine Industry was held on October 11, at the DCC.
A Public Forum for the Establishment of a Promotion Center and a New R&D Project to Support the Genetic Medicine Industry was held on October 11, at the DCC.
A forum was held for discussions to nurture the genetic-based bio-medicine industry.  
 
The "Public Forum for Establishment of Promotion Center and  New R&D Project to Support the Genetic Medicine Industry" held on October 11 was hosted at the Daejeon Convention Center.  
 
Hosted by Daejeon Metropolitan City and organized by Daejeon Techno Park, this public forum served as a platform to collect opinions from people involved in the project, civic leaders and concerned citizens regarding plans to create an infrastructure for the promotion of the genetic medicine industry and to build a consensus. Joined by more than 70 people from the local government, universities, research institutes, hospitals and biotech firms, the event provided an opportunity to share and discuss opinions regarding the establishment of the promotion center as well as the current state of the genetic medicine industry.  
 
With the advancement of the fourth industrial revolution, an era of precision medicine has been ushered in by the bio-healthcare industry that pursues treatments tailored to individuals. As the medical paradigm has shifted from treatment to prevention, the axis for medical services is moving toward customized preventative management, raising the need to create an environment that could enhance technological competitiveness and increase the business success rate in South Korea.  
 
In this context, Daejeon City and Daejeon Techno Park have set out to create a new growth engine for the biotech sector by focusing on the genetic medicine industry with its high future growth potential. Based on this, a project has been planned to install infrastructure and pursue R&D activities through a promotion center based on genetic medicine. 
 
Moon Changyong, Director General of the Science Industry Bureau of Daejeon Metropolitan City, said, "I will make a contribution toward solidifying the competitiveness of local companies and creating jobs by supporting the development and business of innovative healthcare technologies through the promotion of genetic medicine as a specialized industry. I will make the utmost effort for this project to be reflected in the government’s preliminary feasibility study." 
 
Choi Sooman, President of Daejeon Techno Park, added, "Active participation is needed from many people concerned for the further advancement of the biomedicine sector that is growing to a global scale. I hope that this public forum helped entrepreneurs to refine their business plans and will enable them to gain business momentum down the road."  
 
Meanwhile, Daejeon city plans to build a promotion center with an investment of about 150 billion KRW between now and 2025 under a specific business plan to nurture the genetic medicine industry. Their business objective is to acquire 20 new successful IPOs of through the development of core technology in genetic medicine and the establishment of infrastructure conducive to commercialization. 

Panelists discussing the creation of a promotion center.
Panelists discussing the creation of a promotion center.

2.Network for cooperation between Daejeon Techno Park and South Australia···expectations for global growth in bio-industry  
- On October 15, a "Global Networking Session for Companies from Daejeon TP and South Australia" was held at Daejeon Techno Park. 
- Presentations made by companies from Daejeon Techno Park and South Australia… information exchanges during a visit to GMP facilities

"Global Networking Session for Companies from Daejeon TP and South Australia" was held at Daejeon Techno Park on October 15. Participants are expected to build cooperative relations through networking.
"Global Networking Session for Companies from Daejeon TP and South Australia" was held at Daejeon Techno Park on October 15. Participants are expected to build cooperative relations through networking.
A networking session was held for development and cooperation in the bio-medicine industries of Daejeon Techno Park and South Australia.  

On October 15, 2019, a "Global Networking Session for Companies from Daejeon Techno Park and South Australia" took place at Daejeon Techno Park (Daejeon TP). The aim of the gathering was to promote cooperation among biotech firms in Daejeon TP and South Australia and to share know-how in each country's bio-industry. 

At the event, introductions were made regarding the bio-healthcare industries in Daejeon TP and South Australia, followed by presentations of biotech firms.  

Cho Gunho, Chairman of the Bio Convergence Center at Daejeon Techno Park, introduced the Bio Convergence Center. He said, "Daejeon TP has offered supportive services for companies to develop and commercialize new technologies under organic, collaborative system among the industry, academia, research institutes and government to foster Daejeon's four major strategic industries and turn traditional industries into higher value-added businesses. We are especially focused on the growth of the bio-medicine industry including GMP facilities, networking with bio-venture towns, training and marketing.

Jane Kelly, CEO of CMAX, elaborated on the healthcare industry in South Australia, saying, "Australia is a country with a lot of start-ups, diverse populations and robust data mobility, with good conditions for the health industry. In particular, the South Australian Government is investing a lot of money in the healthcare industry."

Firms from Daejeon TP and South Australia share information through dialogue.
Firms from Daejeon TP and South Australia share information through dialogue.
Subsequently, firms supported by Daejeon TP such as Ybiologics, Biocure Pharm, PharmABcine, Alteogen and Seasun Therapeutics gave presentations regarding their companies and future directions.

South Australian companies such as CMAX, Avance Clinical and Syneos Health also introduced their corporations through presentations. 

After the presentations, participants went to GMP facilities in Daejeon TP and spent some time exchanging information. 

Maeng Piljae, Chairman of the Bio-Healthcare Association, said, "As biotech firms pursue global growth, South Australia will become a good partner for further growth. I hope that this network session will open up a cooperative platform that enables us to understand each other and establish a foothold for mutual growth."

Chairman Cho also added to the introduction of Daejeon TP by saying, "As a city of science, Daejeon is home to many research institutes including the research centers of large conglomerates. It has good conditions conducive to company growth such as cooperation among many start-up firms and companies." 

After the presentations, visits were made to GMP facilities in Daejeon Techno Park.
After the presentations, visits were made to GMP facilities in Daejeon Techno Park.
저작권자 © 헬로디디 무단전재 및 재배포 금지